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Abstract 
 
The E3 ubiquitin ligase Cbl plays a vital role in the trafficking of ligand-bound 
EGF-R through the endocytic pathway to its subsequent degradation. The RING finger 
tail region of the Cbl protein is thought to be critical to this process. Previous studies 
demonstrated that amino acid substitutions at position 431 or 434 of Cbl can disrupt the 
normal trafficking of EGF-R. Despite these previous findings regarding trafficking, the 
role of these mutations on EGF-R signaling has yet to be examined. In this study, we aim 
to begin to test the effects on signaling of the V431A and F434A mutations in a cellular 
context by developing pertinent plasmid constructs and generating stable, inducible cell 
lines for the signaling studies. 
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Chapter I: Introduction 
One characteristic of many cancers is cellular hyperproliferation associated with 
an abnormal increase in the activity of the epidermal growth factor receptor (EGF-R) (5, 
6). Balanced regulation of this receptor tyrosine kinase is crucial for normal growth and 
development: while an absence of EGF-R signaling is lethal to knockout mice (10, 15), 
excessive signaling can cause cancer to develop (3). Research into the mechanisms used 
by normal cells to regulate EGF-R may reveal new molecular targets for novel anticancer 
therapies.  
Regulated receptor trafficking and degradation are required to maintain normal 
EGF-R levels and signaling. One mechanism of signaling suppression involves EGF-R 
trafficking through the endocytic pathway to lysosomes, where the receptor is degraded. 
In this pathway, ligand-activated EGF-R dimerizes and is ubiquitinated at the cell surface 
by the E3 ubiquitin ligase Cbl. Ubiquitinated receptors are internalized on vesicles that 
fuse with early endosomes. At this stage, EGF-R is either recycled to the cell surface or 
sorted onto the luminal membranes of multivesicular bodies (MVBs), which are more 
mature forms of the sorting endosomes. Delivery to the endosome lumen physically 
separates activated receptors from their cytosolic signaling partners. It also targets the 
ubiquitinated proteins for lysosomal delivery. This results in the destruction of the 
receptors and their associated proteins. Lysosomal degradation is a definitive mechanism 
for EGF-R signaling termination (1, 7, 13).  
There are three different types of Cbl proteins found in humans, each containing 
several different functional domains. The region of Cbl most significant to this project is 
an evolutionarily conserved region comprising the first 436 amino acids (Figure 1). 
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Domains included in this conserved region are the TKB domain, the linker (L) region, the 
RING finger (RF) domain, and the RF tail -- which is the focus of this project. The RF 
tail, made up of less than 20 amino acids, is vital to the proper functioning of the entire 
Cbl protein. Truncation of Cbl to amino acid 436 results in a functional protein. Removal 
of three amino acids has been shown to result in a nonfunctional Cbl protein. As 
mentioned above, Cbl belongs to the family of proteins known as E3 ubiquitin ligases. 
During the process of ubiquitination, the E3 ligase acts as an adaptor molecule for 
transfer of an ubiquitin molecule to the protein substrate being targeted for degradation 
(Figure 2). 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 1.  Graphic representation of the Cbl protein. 
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Figure 2.  The ubiquitination pathway.
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The Lill laboratory has been investigating the nature of molecular complexes that 
regulate EGF-R endocytic trafficking downstream of internalization. Their recently 
published work revealed important roles for the proteins Cbl and hepatocyte growth 
factor-regulated tyrosine kinase substrate (Hrs) in controlling a newly identified EGF-R 
trafficking checkpoint (12, 15). At this checkpoint, EGF-R-associated Cbl enhances the 
tyrosine phosphorylation and ubiquitination of the Hrs protein. Hrs is a critical regulator 
of endosome docking and fusion (14). Hrs phosphorylation causes Hrs degradation, 
removing it from endosomal EGF-R/Cbl complexes. As a result, Hrs no longer inhibits 
the fusion and maturation of endosomes, allowing EGF-R/Cbl complexes to proceed to 
the endosomal lumen.  
Figure 3.  The endocytic pathway leading 
to multivesicular body formation. (Left) 
Ligand-activated EGF-R is: ubiquitinated 
at the cell surface; internalized on 
vesicles that fuse with early endosomes; 
and either recycled or sorted onto 
lumenal membranes that are internalized 
from endosomal limiting membranes. 
Lumenal vesicle formation, initiated at 
early endosomes, is complete at late 
endosomes (multivesicular morphology).  
Lysosomal delivery allows for 
destruction of internal membranes and 
their cargo. (Right) Proteins important for 
EGF-R trafficking.  Eps15 and Epsin 
bind ubiquitin and are involved in EGF-R 
internalization. Endosomal ubiquitin-
binding receptors (Hrs-STAM and 
ESCRT-I, which contains the ubiquitin-
binding protein Tsg101) bind EGF-R and 
direct it to MVB internal m
Transport of EGF-R 
to Lysosomes
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Structure-function studies in the Lill laboratory have shown that the RF tail is 
essential for Hrs regulation. Single amino acid substitutions of V431A and F434A in the 
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RF tail domain result in Cbl proteins that cannot regulate Hrs properly. The V431A 
mutant blocks activated EGF-R at the cell surface, so it never encounters Hrs on 
endosomes. The F434A mutant has a more interesting phenotype: it allows receptor/Cbl 
complexes to move to endosomes, where Hrs phosphorylation takes place. However, this 
phosphorylated Hrs does not get degraded. Instead, it remains on the endosomes and 
blocks endosome fusion from occurring. The Cbl F434A mutant therefore represents a 
unique tool for the molecular analysis of how normal (wild type) Cbl controls the fusion 
checkpoint to direct activated receptors to luminal vesicles and lysosomal degradation. If 
we can determine why wild type Cbl is functional and F434A is not, we will understand a 
new regulatory step in the EGF-R degradation process.  
 The primary focus of this project was to develop experimental reagents to address 
the question “What impact does RF tail mutation have on EGF-R signaling due to the 
deregulation of the V431- or F434-dependent trafficking checkpoint?” 
Chapter II: Methods 
Plasmids.  The parent construct pTRE-GFP-Cbl-N was generated by first carrying out a 
mutagenic PCR procedure using the lab-supplied plasmid pcDNA3-GFP-Cbl-N and the 
Platinum Taq HiFi Polymerase, dNTPs, MgSO4, and buffer from Invitrogen. A lab-
supplied stock of the primer IA-193 (5’ – GCGGTACCATGAGTAAAGGAGAAGAA 
CTCTTC – 3’; Integrated DNA Technologies, IDT) was utilized as the upstream primer 
in order to introduce a KpnI restriction site just upstream of the GFP gene. For the 
downstream primer, a new oligonucleotide primer, OH-019 (5’ – CGTCTAGACTATCA 
GGGAGTTGGTTCACATAAGCC – 3’; IDT), was created. The resulting PCR product 
was characterized by electrophoresis on a 1.0% agarose/TAE gel. The size of 1.8 kbp 
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confirmed the success of the procedure. The PCR product was then digested with KpnI 
and XbaI, as was pTRE, allowing for ligation of the insert (GFP-Cbl-N) to the linearized 
vector (pTRE), using T4 DNA ligase and corresponding buffer (BioLabs). The DNA 
constructs were then used to transform competent JM109 E. coli cells, followed by 
plating on LB-ampicillin agar. After purification of DNA prepared from the resulting 
colonies using a Maxiprep kit (QIAgene), the DNA was digested with KpnI and XbaI and 
then separated on a 1.0% agarose/TAE gel for characterization of the parent construct, 
pTRE-GFP-Cbl-N.  
This was followed by sequential digestion and insertion of the alternate Cbl 
sequences (wt, V431A, and F434A) using the restriction enzymes BamHI and XbaI, 
followed by ligation, transformation, and purification of DNA, as mentioned above and 
in the Results section. 
Mammalian cell lines, their passaging and maintenance.  This study utilized HEK 
293-TRE Tight-Tet-ON Advanced cells (Clontech). HEK 293 is an immortalized human 
embryonic kidney cell line of epithelial morphology. The cells express very low levels of 
EGF-R and related receptor tyrosine kinases; by introducing expression constructs into 
them, we can evaluate the impact of co-expressed proteins on EGF-R homodimers, which 
are the normal targets for Cbl. The HEK 293 cell model system has been proven by the 
Lill lab to differentiate activities of wild type and mutant Cbl proteins in assays of EGF-R 
ubiquitination, downregulation, degradation, and signaling (9, 12, 15). By moving our 
studies into the HEK 293-TRE tight-Tet-ON Advanced cells, we have maintained our 
experimental system while adding the ability to express the Cbl protein of interest only 
when it is desired. 
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The parental and derived HEK 293-TRE tight-Tet-ON Advanced cell lines were 
passaged regularly at subconfluence, using trypsin/EDTA solution and an established 
laboratory protocol. The cells were maintained in DMEM containing fetal bovine serum 
(10%), 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 100 units/mL 
penicillin-streptomycin and 20 mM HEPES, in an atmosphere containing 5% CO2. 
Growth of bacteria and large-scale plasmid preparation.  Frozen glycerol stocks of 
bacteria carrying expression constructs for EGF-R and constitutively expressed GFP-
tagged wild type (wt), V431A, F434A, and –N mutant Cbl were reported previously (16) 
and available in the laboratory. Large-scale bacterial cultures were grown in the presence 
of ampicillin. The bacteria were then processed for plasmid preparation using the 
QIAGEN Maxiprep system. Newly developed pTRE-GFP and pTRE-GFP-Cbl-wt, -
V431A, -F434A, and -Cbl-N plasmids were propagated and purified identically. 
Transfection of Mammalian Cells.  Established techniques were used to introduce the 
mammalian expression constructs into the cells to be tested. HEK 293-TRE tight-Tet-ON 
Advanced cells were transfected using a modification of the calcium phosphate 
precipitation technique (4). DNA precipitates/complexes were normalized for total DNA 
and promoter input. Transfections resulted in either transient expression of the proteins of 
interest for short-term assays or in the development of clonally derived inducible cell 
lines. This was important, as stable cell lines continuously expressing wild type Cbl 
utilize undefined compensatory mechanisms to override Cbl’s suppression of RTK 
signaling, thus confounding readouts of Cbl’s impact on cell signaling and growth, and 
perhaps also receptor trafficking (2, 11).  
Chapter III: Results 
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A. Generation of constructs for inducible mammalian expression of GFP and GFP-
Cbl fusion proteins. 
 Cbl RF tail residues V431 and F434 are critical for EGF-R down-regulation and 
degradation. We wished to determine whether these residues influence receptor signaling 
in a cellular context. Over-expression of wild type Cbl has been shown to select for the 
outgrowth of cells that have bypassed Cbl-regulated signal suppression (7, 11). To avoid 
this problem, tetracycline-inducible constructs encoding GFP or GFP-tagged wildtype, 
V431A, F434A, or the transforming truncation mutant Cbl-N were developed as 
specified in the Methods section.  
The original intention was to generate five plasmid constructs (Figure 4) by 
carrying out digestions of the donor plasmids pcDNA3-GFP-2xStop, GFP-Cbl-wt, -N, -
V431A, and -F434A using the restriction enzymes HindIII and XbaI, followed by 
insertion of the different GFP-Cbl DNA fragments into the like-digested pTRE-tight 
cloning vector(Figure 5). The general design of the expected insert donor constructs is 
shown in Figure 6. But upon attempting this digestion/insertion strategy, I discovered that 
the Cbl coding sequence possesses additional restriction sites for the enzyme HindIII. 
This problem was not observed in the pcDNA3-2xStop plasmid, which possesses only a 
GFP insert and no Cbl coding sequence. Therefore, the pTRE-GFP construct (Figure 7) 
was generated using the above-mentioned strategy, while the pTRE-GFP-Cbl-wt, -N, -
V431A, and –F434A constructs were not (Figure 8). 
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Figure 4:  Basic composition of inducible constructs 
to be generated. The goal was to generate five 
different plasmid constructs using the pTRE-tight 
cloning vector. The inserts, GFP or GFP-Cbl, would 
be inserted downstream of the Ptight inducible 
promotor.  
Ptight
XhoI 
pTRE-GFP  or 
pTRE-GFP-Cbl 
GFP or GFP-Cbl
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CblGFP 
Figure 5:  Specific details of the cloning vector,  
pTRE-Tight, and the sequences to be cloned. Five  
different inserts were cloned into the vector  
pTRE-Tight. These included: GFP, GFP-Cbl-N, GFP 
-Cbl-wt, GFP-Cbl-V431A, and GFP-Cbl-F434A. 
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Cbl-wt,V431A,F434A GFP 
Figure 6: Representation of the donor plasmids that 
provide inserts for cloning. The Lill lab provided all of 
the donor plasmids. These included: pcDNA3-2xStop, 
pcDNA3-GFP-Cbl-N, -wt, -V431A, and -F434A. 
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Figure 7:  pTRE-Tight-GFP-2xStop, 
the first construct generated.  
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 To generate the pTRE-GFP construct, large amounts of HindIII/XbaI-treated 
pTRE-tight and pcDNA3-2xStop were separated by gel electrophoresis (Figure 9). The 
now-linear pTRE vector and the GFP insert were then purified, ligated to each other, and 
then used to transform E. coli cells. To ensure that the correct plasmid had been 
generated, multiple clones were characterized through digestion and gel electrophoresis 
(Figure 10). Of the five clones characterized, four were deemed adequate based on the 
size of the DNA fragments. The sample represented in lane 6 from Figure 10 was chosen 
for further use in the project. 
We determined that the most effective solution for generation of the remaining 
constructs was to create a parent construct with a new restriction site incorporated 
upstream of the genes of interest (Figure 11). The generation of the parent construct is 
described in the Plasmids section of Methods. Mutagenic PCR was carried out on 
pcDNA3-GFP-Cbl-N and products were separated on an agarose gel (Figure 12). Both 
the PCR product and the cloning vector pTRE-Tight were preparatively digested using 
the restriction enzymes KpnI and XbaI (Figure 13). The results of the cloning and 
purification of the new construct are characterized in Figure 14.  
Our next goal was to create the experimental constructs: pTRE-GFP-Cbl-wt, 
pTRE-GFP-Cbl-V431A, and pTRE-GFP-Cbl-F434A. The general design of the 
experimental constructs is illustrated in Figure 15. The parent construct was preparatively 
digested using the restriction enzymes BamHI and XbaI, as were the donor constructs 
(Figure 16). After the ligation, transformation, and purification of the clones, gel 
electrophoresis was used to confirm the generation of the correct constructs (Figure 17). 
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KpnI 
Ptight
Figure 11:  Representation of the parent pTRE 
construct for cloning of Cbl full-length sequences. 
The goal was to generate the parental construct 
pTRE-GFP-Cbl-N with a new KpnI restriction site 
just upstream of the GFP-Cbl-N region but down 
stream of the Ptight inducible promotor.  
pTRE-GFP-Cbl-N 
(parent construct) 
Cbl-NGFP
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Figure 15.  Cloning sites used for insertion of Cbl 
sequences into the parent vector to generate 
experimental constructs. The goal was to generate the 
constructs pTRE-GFP-Cbl-wt, -V431A, and -F434A 
from the parent construct pTRE-GFP-Cbl-N. 
pTRE-GFP-Cbl 
GFP Cbl
XbaI BamHIKpnI 
Ptight
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Once all of the constructs had been produced, the ensuing step was to transfect 
HEK 293 TET-On Advanced mammalian cells for transient expressor studies. This was 
carried out for the purpose of testing the inducibility of the constructs in the presence of 
the antibiotic doxycycline. As shown in Figure 18, the addition of 100 ng/mL of 
doxycycline to the transfected cells resulted in the expression of the genes immediately 
downstream from the Ptight promotor on each plasmid. Also important was the absence of 
any signal in the non-stimulated samples, confirming the tightness of the system. In all, 
this procedure showed that the Ptight promotor is indeed doxycycline-induced.  
A second transient transfection was carried out in order to determine the optimum 
concentration of doxycycline necessary for induction of the promotor, while limiting 
toxicity to cells. The results of this procedure, known as a dose response assay, are 
depicted in Figure 19. Concentrations of doxycycline ranging from 0 to 750 ng/mL were 
added to transiently transfected cells. Cell proteins were harvested and analyzed by 
Western blotting using an antibody against GFP. The sizes of the protein signals in the 
top panel of Figure 19 correspond well with the known size of the GFP-Cbl-wt fusion 
protein – approximately 147 kD. The strength of the bands increases as the concentration 
of doxycycline increases, up to 250 ng/mL. Beyond this concentration, the bands are 
about equal in appearance. In addition to this, concentrations of doxycycline exceeding 
100 ng/mL seemed to have negative effects on the cells, which included the following: 
slow growth, morphological change, lack of adherence to the plate bottom, and cell 
death. Thus, it was determined that the optimal balance between toxicity and protein 
expression was achieved at a doxycycline concentration of 100 ng/mL.    
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To produce stable cell lines, the cells were transfected with the experimental 
constructs, as well as a hygromycin selection marker. Upon treatment with hygromycin, 
individual colonies were selected. GFP proteins were then induced by doxycycline 
treatment, harvested and analyzed by Western blotting using an antibody against GFP. 
Cell lines of the pTRE-GFP (Figure 20) and pTRE-GFP-Cbl-N (Figures 21 and 22) 
constructs were successfully produced.  A stable cell line may also have been produced 
for the pTRE-GFP-Cbl-F434A mutant construct, as shown in lane 18 of Figure 22.                               
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Chapter IV: Discussion 
This investigation has resulted in the generation of multiple plasmid constructs 
that can and will be used in the future by the Lill lab for the purposes of studying the 
effects of ectopically expressed wild type and mutant forms of Cbl on EGF-R signaling in 
a cellular context. The generation of the pTRE-GFP construct is significant because it 
will serve as a control for the effects of GFP on cellular functions, which is necessary 
since all of the other constructs will express GFP-Cbl fusion proteins. The pTRE-GFP-
Cbl-N construct serves as a positive control for the induction of a cancer phenotype and 
oncogenic signaling.  Cbl-N is a known transforming agent that has been shown to cause 
tumors in animals (8).  It lacks the linker region, RING finger domain, and RING finger 
tail that have been shown to contribute to Cbl’s evolutionarily conserved regulation of 
EGF-R (10, 15). 
The pTRE-GFP-Cbl-wt construct will provide the reference level of signaling by 
the wild type Cbl protein, against which the full-length RF tail mutant forms will be 
compared. The two mutant constructs, pTRE-GFP-Cbl-V431A and pTRE-GFP-Cbl-
F434A, will allow us to determine the effects of two specific mutations in the RF tail 
region of the Cbl protein on EGF-R signaling.  The Lill laboratory has already shown that 
these mutations compromise EGF-R degradative trafficking (16). Subsequent signaling 
studies will address the question of whether changes in receptor tyrosine kinase 
trafficking lead to changes in receptor signaling, either at the cell surface or on 
internalized endosomes. 
Signaling by the Cbl RF tail mutants will be analyzed by Western blotting.  The 
lysates to be tested will come from matched sets of unstimulated and EGF-stimulated 
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cultures that have been induced with doxycycline to express a wt or mutant Cbl protein.  
The first signaling pathway to be tested will be the PLC- pathway, which depends upon 
the presence of the EGF-R at the cell surface.  I will compare the V431A-induced signal 
against the signal from wt Cbl, quantifying both the total PLC- and phospho-PLC- 
levels. I predict that the signaling through this pathway will remain elevated for 
significantly longer time periods in V431A cells than in cells expressing wild type Cbl, 
since internalization of EGF-R is blocked by this mutant.  
With the pTRE-GFP-Cbl-F434A mutant, on the other hand, we expect PLC- 
signaling levels to be comparable to wild type cells, since this mutant does not affect 
internalization of EGF-R.  However, we predict ligand-dependent increases in MAP 
kinase and Akt signaling (which have been suggested to occur both at the plasma 
membrane and inside of the cell on endosomes) with a longer duration in the F434A 
mutant than in wild type cells, because degradation of activated EGF-R in F434A-
expressing cells is blocked at the level of endosome fusion after internalization has 
occurred (16).  This could allow EGF-R to continuously initiate signaling even from the 
limiting membrane of endosomes.  
I have succeeded in generating stable cell lines that inducibly express proteins 
from two of the constructs that I developed for my thesis project (pTRE-GFP and pTRE-
GFP-Cbl-N), and possibly for pTRE-GFP-Cbl-F434A as well (Figure 22, lane 18).  This 
has laid the ground work for the signaling experiments mentioned above.  The use of 
stable inducer cell lines, as opposed to transiently transfected cells, will mitigate the issue 
of low transfection rates, since all cells in a given clonal cell line will theoretically 
possess and express the plasmid of interest.  The use of inducible Cbl expressors also will 
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mitigate a problem that was noted in previous studies:  continuous expression of the 
signaling suppressor Cbl selects for the outgrowth of stable expressor lines that have 
mutated to bypass Cbl’s function (2).  The inducible lines should not have this problem if 
they are maintained in the absence of doxycycline.   
After we have established clonal inducible cell lines for the remaining three 
plasmids and carried out the signaling experiments in vitro, all of the control and RF 
mutant pTRE-tight Cbl constructs can be utilized further for transgenic mouse 
experiments.  Expression of the desired proteins can be induced by adding doxycycline to 
the food or water of the transgenic mice, which can then be monitored for evidence of 
oncogenic signaling.  Tumorigenesis is expected with the GFP-Cbl-N construct, and it 
may also be caused by the V431A and F434A mutants.  
In summary, using the RF tail mutant expression constructs, the Lill lab will now 
be able to undertake studies of Cbl trafficking and signaling in the context of intact 
mammalian cell cultures and in transgenic mice.  The resulting data will show whether 
the Cbl RF tail, which controls the endocytic trafficking of EGF-R, also is a key regulator 
of the receptor’s oncogenic signaling.  
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